Stocklytics score rationale: value 60, quality 52, growth 100.
Financials
2020
2021
2022
2023
2024
2025
0
0
0
0
0
0
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of…
Forecast
Consensus Buy from 19 analysts. Average price target $50.00, +293.1% versus the current price. Low $50.00. High $50.00.
Analysts have an average 12-month price target of $50.00 for MoonLake Immunotherapeutics (MLTX), 296.4% above the current price of $12.62. Of 19 analysts covering the stock, 15 rate it Buy or Strong Buy, 2 Hold, and 2 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
MLTX price target
12-month price target
Low
$50.00
Average
$50.00
High
$50.00
The average is 296.4% above the current price of $12.62.
Is MoonLake Immunotherapeutics a buy or sell?
Of 19 analysts, 15 rate MoonLake Immunotherapeutics Buy or Strong Buy, 2 Hold, and 2 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
MoonLake Immunotherapeutics earnings and revenue forecast
The Stocklytics Score for MLTX is 71 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
MLTX forecast FAQs
What is the MLTX price target?
$50.00 average, with a published range of $50.00 to $50.00.
Is MoonLake Immunotherapeutics a buy or sell?
The consensus is Buy from 19 analysts. This is not a recommendation.
What is the MoonLake Immunotherapeutics stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -3.37. The average revenue estimate is $0.
What will MLTX be worth in 2030?
No reliable forecast exists that far out.
When is MoonLake Immunotherapeutics's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.